{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \nThe following is a summarized molecular profile from MSK-IMPACT.\nBased on this profile, answer with the appropriate treatments for this patient in the format above.\nPatient ID: P-0000036\nAge: 68\nGender: Female\nSample ID: P-0000036-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Primary\nTumor Purity: 30.0%\n=============\nDNA Variants:\nAR c.676T>G (p.L226V) - in 14.000000000000002% of 584 reads\nERBB2 c.3044G>A (p.G1015E) - in 42.0% of 354 reads\nFBXW7 c.336_344del (p.D112_E114del) - in 40.0% of 378 reads\nIRS1 c.1382A>G (p.E461G) - in 44.0% of 418 reads\nNOTCH4 c.2443T>G (p.C815G) - in 48.0% of 296 reads\nTP53 c.991C>T (p.Q331*) - in 6.0% of 311 reads\nTSHR c.202C>T (p.P68S) - in 50.0% of 516 reads\nCNA Data:\nNo CNA data found for the specified patient ID.\nStructural Variants:\nROS1 - SLC34A2 (TRANSLOCATION)\n\n    ",
    "response": "{\n    \"Treatment 1\": {\n        \"Disease Name\": \"Lung Adenocarcinoma\",\n        \"Disease Phase or Condition\": \"Metastatic\",\n        \"Drug Name\": \"Entrectinib\",\n        \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n        \"Genomic Features\": \"ROS1 - SLC34A2 (TRANSLOCATION)\",\n        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n    }\n}"
}